(A version of this story first appeared on Hemp Industry Daily.)
Australia has published a framework for new CBD regulations as it considers relaxing its narcotics scheduling of cannabidiol to make it available over the counter in limited doses.
Australia conducted a safety review of cannabidiol in January, according to Hemp Industry Daily.
CBD is currently listed as a Schedule 4 substance in Australia and therefore available only with a prescription.
Under the proposed change, CBD would become a Schedule 3 substance, meaning no prescription would be required as long as the following conditions apply:
- The cannabidiol is plant-derived or, if it’s synthetic, is subject to certain conditions.
- The maximum recommended daily dose is 60 milligrams or less.
- The product is in packs containing not more than a 30-day supply.
- Cannabidiol comprises 98% or more of the total cannabinoid content of the preparation.
- Any cannabinoids, other than CBD, must be only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the preparation
- The product is for adults 18 and older.
The Australian health department said it is accepting public comments on the new scheduling proposal in accordance with government regulations. The deadline for submissions is May 22.
The proposal will be discussed in June, the agency said.